FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111561593> ?p ?o ?g. }

• W3111561593 abstract "Abstract Background Urothelial bladder carcinoma accounts for around 3.9% cases of all the male cancers in India. Non-muscle-invasive bladder carcinoma (NMIBC) is predominant group which constitute approximately three fourth of the urothelial bladder cancer. Intravesical BCG immunotherapy is the corner stone of today’s NMIBC management. However, as with any other therapy it has its own complications and its interruption due to these adverse effects is a major cause of suboptimal efficacy. The aim of this study was to assess the complications of intravesical BCG therapy and their management in NMIBC patients. Methods This was a retrospective descriptive study conducted between October 2016 and November 2019; a backward review of 149 patients with diagnosis of NMIBC that undergone intravesicle BCG therapy was performed. Patient’s demographical, clinical, diagnostic and procedural data regarding bladder tumour, BCG therapy, its complications and management were collected and analysed. Results Total 149 patients were analysed, comprising 116 males and 33 females. The mean age was of 57.2 ± 6.7 years. Total 85.23% were primary and 14.76% were recurrent tumours. Total 96 patients (64.42%) completed the planned course, while 53 (35.57%) interrupted. The reasons for BCG interruption includes adverse effects (15.4%), progression of disease (6.7%), disease refractory to BCG (4.6%) and disease recurrence during BCG (3.3%). Most of the adverse events occurred in first 6 months and most interruptions occurred after the induction period. Cystitis was the most common observed adverse effect seen in 39.6% patients. Frequency, urgency, haematuria were common presentation. Radical cystectomy was the most common (16.10%) further treatment with patients whose treatment was interrupted. Conclusion BCG is an indispensable therapy available for NMIBC, but it is associated with array of adverse effects and complications, which are the main reasons for poor compliance to BCG therapy. Although BCG-related complications can affect any organ in the body, potentially life-threatening systemic BCG-related infections are encountered in only < 5% of patients. There are some difficulties in diagnosis of the BCG complications because acid-fast staining, culture and PCR test are not always positive; tissue biopsies should be indicated sometimes to evaluate histopathology and presence of M. bovis . A persistently monitored multidisciplinary approach with high index of suspicion and prompt anti-TB therapy can help to derive the maximum benefits while keeping the complications at check." @default.
• W3111561593 created "2020-12-21" @default.
• W3111561593 creator A5025087943 @default.
• W3111561593 creator A5025329607 @default.
• W3111561593 creator A5027544487 @default.
• W3111561593 creator A5031796986 @default.
• W3111561593 creator A5040810731 @default.
• W3111561593 creator A5046480835 @default.
• W3111561593 creator A5086918163 @default.
• W3111561593 date "2020-12-01" @default.
• W3111561593 modified "2023-09-26" @default.
• W3111561593 title "Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience" @default.
• W3111561593 cites W1423791052 @default.
• W3111561593 cites W1517801015 @default.
• W3111561593 cites W1540582961 @default.
• W3111561593 cites W1693577243 @default.
• W3111561593 cites W1970681090 @default.
• W3111561593 cites W1971367567 @default.
• W3111561593 cites W1987030333 @default.
• W3111561593 cites W1995371565 @default.
• W3111561593 cites W1999497118 @default.
• W3111561593 cites W2005126643 @default.
• W3111561593 cites W2007254165 @default.
• W3111561593 cites W2019896103 @default.
• W3111561593 cites W2020301602 @default.
• W3111561593 cites W2026136244 @default.
• W3111561593 cites W2032733252 @default.
• W3111561593 cites W2039069446 @default.
• W3111561593 cites W2039218197 @default.
• W3111561593 cites W2046014008 @default.
• W3111561593 cites W2050525781 @default.
• W3111561593 cites W2051922168 @default.
• W3111561593 cites W2054442907 @default.
• W3111561593 cites W2058196335 @default.
• W3111561593 cites W2059252247 @default.
• W3111561593 cites W2069071140 @default.
• W3111561593 cites W2084794229 @default.
• W3111561593 cites W2088397212 @default.
• W3111561593 cites W2090147925 @default.
• W3111561593 cites W2094054144 @default.
• W3111561593 cites W2094778278 @default.
• W3111561593 cites W2095771511 @default.
• W3111561593 cites W2107944116 @default.
• W3111561593 cites W2132425500 @default.
• W3111561593 cites W2140797233 @default.
• W3111561593 cites W2147633207 @default.
• W3111561593 cites W2151575881 @default.
• W3111561593 cites W2156315580 @default.
• W3111561593 cites W2162130153 @default.
• W3111561593 cites W2169974639 @default.
• W3111561593 cites W2335288327 @default.
• W3111561593 cites W2409438189 @default.
• W3111561593 cites W2410259791 @default.
• W3111561593 cites W2616988051 @default.
• W3111561593 cites W2810757757 @default.
• W3111561593 cites W2904825864 @default.
• W3111561593 cites W2916183155 @default.
• W3111561593 cites W4245921920 @default.
• W3111561593 doi "https://doi.org/10.1186/s12301-020-00099-6" @default.
• W3111561593 hasPublicationYear "2020" @default.
• W3111561593 type Work @default.
• W3111561593 sameAs 3111561593 @default.
• W3111561593 citedByCount "4" @default.
• W3111561593 countsByYear W31115615932021 @default.
• W3111561593 countsByYear W31115615932023 @default.
• W3111561593 crossrefType "journal-article" @default.
• W3111561593 hasAuthorship W3111561593A5025087943 @default.
• W3111561593 hasAuthorship W3111561593A5025329607 @default.
• W3111561593 hasAuthorship W3111561593A5027544487 @default.
• W3111561593 hasAuthorship W3111561593A5031796986 @default.
• W3111561593 hasAuthorship W3111561593A5040810731 @default.
• W3111561593 hasAuthorship W3111561593A5046480835 @default.
• W3111561593 hasAuthorship W3111561593A5086918163 @default.
• W3111561593 hasBestOaLocation W31115615931 @default.
• W3111561593 hasConcept C121608353 @default.
• W3111561593 hasConcept C126322002 @default.
• W3111561593 hasConcept C126894567 @default.
• W3111561593 hasConcept C141071460 @default.
• W3111561593 hasConcept C197934379 @default.
• W3111561593 hasConcept C2779134260 @default.
• W3111561593 hasConcept C2780352672 @default.
• W3111561593 hasConcept C71924100 @default.
• W3111561593 hasConceptScore W3111561593C121608353 @default.
• W3111561593 hasConceptScore W3111561593C126322002 @default.
• W3111561593 hasConceptScore W3111561593C126894567 @default.
• W3111561593 hasConceptScore W3111561593C141071460 @default.
• W3111561593 hasConceptScore W3111561593C197934379 @default.
• W3111561593 hasConceptScore W3111561593C2779134260 @default.
• W3111561593 hasConceptScore W3111561593C2780352672 @default.
• W3111561593 hasConceptScore W3111561593C71924100 @default.
• W3111561593 hasIssue "1" @default.
• W3111561593 hasLocation W31115615931 @default.
• W3111561593 hasOpenAccess W3111561593 @default.
• W3111561593 hasPrimaryLocation W31115615931 @default.
• W3111561593 hasRelatedWork W2002120878 @default.
• W3111561593 hasRelatedWork W2003938723 @default.
• W3111561593 hasRelatedWork W2047967234 @default.
• W3111561593 hasRelatedWork W2118496982 @default.
• W3111561593 hasRelatedWork W2364998975 @default.
• W3111561593 hasRelatedWork W2439875401 @default.

• next